295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)

295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 32; p. S493
Main Authors: Bortot, L., Basile, D., Targato, G., Zara, D., Palmero, L., Alberti, M., Buriolla, S., Noto, C., Pascoletti, G., Poletto, E., Andreetta, C., Russo, S., Mansutti, M., Gerratana, L., Bonotto, M., Fasola, G., Puglisi, F., Minisini, A.M.M.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2021
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2021.08.578